ArticleInflammopharmacology2025
Associations of genetic proxies for non-steroidal anti-inflammatory drugs with increased kidney stone risk: a Mendelian randomization study.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundKidney stones are increasingly common globally, and drug-induced kidney stones are often under-recognized. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used, and their potential link to kidney stones is an area of concern. The aim of this study is to explore the potential relationship between NSAIDs and kidney stones using Mendelian randomization (MR).
methodsNSAIDs target genes were identified, and expression quantitative trait locus data were used to find genetic instruments. We conducted a summary data-based MR analysis to verify associations between genetic instruments and inflammatory factors and then assessed the causal relationship between target gene expressions and kidney stones. Sensitivity analyses, including colocalization analysis, horizontal pleiotropy assessment, investigation of weak instrumental variable impact, use of multiple data sources and methods, and testing of associations between inflammatory factors and kidney stone risk, were performed.
resultsTwelve target genes were identified. After comprehensive analysis, only NEU1 showed a significant genetically proxied association with kidney stone risk. A decrease in genetically proxied NEU1 expression was associated with an increased risk of kidney stones (odds ratio = 0.6, 95% CI 0.47-0.77). Sensitivity analyses supported the reliability of this association. No significant association was observed between tumour necrosis factor-alpha (TNF-α) and kidney stones, suggesting that the NEU1-kidney stone association may be independent of TNF-α.
conclusionsGenetically proxied lower NEU1 expression was associated with higher kidney stone risk. This association appeared independent of TNF-α levels. These findings warrant further mechanistic studies to investigate NEU1-related pathways in nephrolithiasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.